Core Insights - GE HealthCare Technologies Inc. (GEHC) has launched the Genesis portfolio, a cloud-based enterprise imaging software-as-a-service (SaaS) solution aimed at modernizing healthcare data management [1][4] - The Genesis portfolio is designed to address the increasing complexity of healthcare data and IT challenges, providing a flexible and cost-effective alternative to traditional on-premises solutions [2][6] - The launch is expected to drive recurring revenue through cloud-based services, enhancing GEHC's market position and creating a steady stream of subscription-based income [4][5] Company Developments - GEHC's market capitalization stands at $39.59 billion, and the company reported an earnings surprise of 15.1% in the last quarter [5] - The Genesis portfolio includes features such as secure cloud connectivity, reduced imaging data management burdens, vendor-neutral archiving, and AI-powered data migration [10] - Recent strategic moves include the unveiling of the Freelium platform for MR imaging and a partnership with Sutter Health to enhance imaging services [11][12] Market Performance - Following the Genesis announcement, GEHC shares closed flat at $85.36, with a 2.1% decline over the past six months compared to the industry's 5.2% growth [3] - The S&P 500 index increased by 4.6% during the same period [3] Industry Context - The healthcare sector is experiencing a shift towards digital and AI-driven solutions, necessitating scalable and secure systems for efficient patient data management [6][8] - The Genesis portfolio aims to streamline workflows and improve patient care by integrating various hospital IT systems and enhancing data accessibility [8][9]

Core Viewpoint - GE HealthCare Technologies Inc. (GEHC) has introduced Freelium, a next-generation sealed magnet platform aimed at transforming Magnetic Resonance (MR) imaging by using less than 1% of helium compared to traditional systems, thereby enhancing sustainability and accessibility in helium-scarce regions [1][6]. Group 1: Product Features and Benefits - Freelium utilizes intelligent magnet technology that supports AI-enabled solutions, featuring remote monitoring and automated recovery to ensure consistent performance and minimize downtime [2][8]. - The platform is designed to reduce operational costs without compromising performance, operating without additional cooling or power requirements, and includes intelligent sensor technology for remote monitoring [8]. - Freelium's environmentally friendly design aligns with GEHC's sustainability goals, having already saved approximately 3 million liters of helium through its innovative magnet technology [9]. Group 2: Market Impact and Financial Performance - Following the announcement of Freelium, GEHC shares closed flat at $87.35, with a 3% increase over the past six months, compared to the industry’s 7.5% growth and the S&P 500's 8.1% increase during the same period [3]. - The introduction of Freelium is expected to drive long-term stock growth by providing a sustainable and cost-efficient MR imaging solution, potentially increasing GEHC's market share and revenue in the medical imaging sector [4]. - GEHC currently has a market capitalization of $39.95 billion and reported an earnings surprise of 15.1% in the last quarter [5]. Group 3: Strategic Developments - GEHC has made strategic moves to enhance its imaging services and AI capabilities, including a partnership with Sutter Health to improve access to innovative imaging services [10]. - The company is advancing its AI-driven technologies, with recent submissions for FDA clearance and the introduction of new imaging systems aimed at improving diagnostic accuracy and workflow efficiency [11][12].

Group 1 - Zacks Premium offers various tools for investors, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1][2] - The Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, helping investors identify securities with high potential to outperform the market [2][3] Group 2 - Each stock receives a rating from A to F based on its value, growth, and momentum, with A being the highest score indicating a better chance of outperforming [3] - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, and Price/Sales [3][4] - The Growth Score focuses on a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow [4] - The Momentum Score helps investors capitalize on price trends, using factors like one-week price change and monthly earnings estimate changes [5] Group 3 - The VGM Score combines all Style Scores, providing a comprehensive indicator for investors who utilize multiple investing styles [6] - The Zacks Rank employs earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7][8] Group 4 - Investors are encouraged to select stocks with Zacks Rank 1 or 2 and Style Scores of A or B to maximize returns [10] - Stocks with lower ranks, such as 4 (Sell) or 5 (Strong Sell), even with high Style Scores, may still face downward price trends [11] Group 5 - GE HealthCare Technologies Inc. is a leading provider of medical technology and digital solutions, formed on January 3, 2023, after a spin-off from General Electric [12] - GE HealthCare has a Zacks Rank of 3 (Hold) and a VGM Score of B, with a Value Style Score of B due to a forward P/E ratio of 19.39 [12][13] - The company has seen upward revisions in earnings estimates, with the Zacks Consensus Estimate increasing by $0.01 to $4.70 per share, and an average earnings surprise of 6.2% [13]

Core Insights - GE HealthCare reported fourth-quarter adjusted EPS of $1.45, an increase from $1.18 a year ago, surpassing the consensus estimate of $1.26 [1] - The company achieved sales of $5.32 billion, nearly matching the consensus of $5.33 billion, reflecting a 2% year-over-year growth on both reported and organic bases [1] - Revenue growth was primarily driven by Advanced Visualization Solutions (AVS) and Pharmaceutical Diagnostics (PDx), with notable strength in the U.S. market [1] Financial Performance - For 2024, GE HealthCare recorded revenues of $19.7 billion, a 1% increase year-over-year on both reported and organic bases [2] - Net income attributable to GE HealthCare rose to $720 million from $403 million a year ago, while Adjusted EBIT increased to $994 million from $837 million [3] - The total company book-to-bill ratio was 1.09 times, with total orders increasing by 6% organically year-over-year [2] Management Commentary - GE HealthCare President and CEO Peter Arduini expressed satisfaction with the strong momentum in orders, backlog, and book-to-bill ratios observed in the fourth quarter [4] - The company continues to experience revenue growth driven by demand in AVS and PDx, alongside robust margin expansion and earnings growth [4] Future Guidance - GE HealthCare provided guidance for 2025, factoring in the impact of recently implemented U.S. tariffs on products from China [4] - The company anticipates organic revenue growth of 2% to 3% year-over-year, with an expected adjusted EBIT margin of 16.7%-16.8% [6] - Adjusted EPS is projected to be between $4.61 and $4.75, compared to the consensus of $4.66, with free cash flow expected to be at least $1.75 billion [6] Stock Performance - GEHC stock experienced a rise of 9.01%, reaching $93.64 during the last check on Thursday [5]

Financial Data and Key Metrics Changes - For Q4 2024, the company reported revenues of $5.3 billion with organic revenue growth of 2% [17] - Global sales growth, excluding an approximate 200 basis point impact from China, was up 4% for Q4 [18] - Adjusted EBIT margin was 18.7%, up 260 basis points year-over-year, driven by productivity and volume [19] - Adjusted EPS for Q4 was $1.45, up 23% year-over-year [20] - For the full year 2024, revenues were $19.7 billion, growing 1% organically [20] Business Line Data and Key Metrics Changes - Imaging segment organic revenue was flat year-over-year, with EBIT margin up 200 basis points due to favorable price and product mix [27] - Advanced Visualization Solutions (AVS) organic revenue grew 4% year-over-year, with EBIT margin increasing by 240 basis points [29] - Patient Care Solutions had flat organic revenue growth, with EBIT margin declining 50 basis points due to inflation [30] - Pharmaceutical Diagnostics achieved 9% organic growth with an EBIT margin of approximately 33% [32] Market Data and Key Metrics Changes - The U.S. market showed robust growth, with half of surveyed customers expecting increased imaging investment [6][7] - In China, there was a slight improvement in orders growth, aligning with previous commentary [7] - The company anticipates negative sales performance in China for the first half of 2025, with sequential improvement expected in the second half [37] Company Strategy and Development Direction - The company is transitioning from an imaging company to a healthcare solutions provider, focusing on long-term enterprise deals [9][10] - In 2024, the company closed 50 enterprise deals globally, with a total value exceeding $5 billion since becoming independent [10] - The company introduced approximately 40 innovations in 2024, contributing to a strong new product introduction vitality of about 50% [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver margin expansion and highlighted a strong backlog and orders momentum [41][46] - The company is taking a measured approach to guidance for 2025, considering market dynamics including China and tariffs [46] - Management emphasized the importance of innovation and strategic partnerships in driving future growth [42][43] Other Important Information - The company announced a planned acquisition of NMP to enhance radiopharmaceutical distribution capabilities in Japan and other Asian markets [14] - A significant investment of $138 million was announced to expand the Contrast Media manufacturing facility in Cork, Ireland [34] - The company was recognized by Fortune as one of the World's Most Admired Companies for 2025 [47] Q&A Session Summary Question: Margin dynamics and future expectations - Management noted that the 18.7% margin in Q4 was a record, with strong performance driven by volume, mix, and price [55] - Future guidance remains focused on mid-term expectations of 20% plus margins, with confidence bolstered by recent performance [60] Question: Insights on the order environment in China - Management confirmed that order growth in China is expected to improve in the first half of 2025, with the majority of sales translation occurring in the second half [72][75] Question: Competitive dynamics and market environment - Management indicated improvements in the CapEx environment globally, particularly in the U.S., with strong growth in procedures driving demand [78][80] - The competitive landscape remains strong, with the company confident in its ability to win in various markets [81][82] Question: Sutter Health deal specifics - The Sutter Health deal is valued at $1 billion over seven years, with orders expected to come into the order book in the first half of the year [132][137] Question: M&A strategy for 2025 - Management emphasized the importance of tuck-in M&A, focusing on strategic fits that enhance the company's healthcare solutions capabilities [140][142]

Core Insights - GE HealthCare (GEHC) reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.45, exceeding the Zacks Consensus Estimate of $1.26 by 15.1%, and showing a year-over-year improvement of 22.9% [1] - The company's shares gained 0.7% in pre-market trading following the earnings report, with a 3% increase over the past six months compared to the industry's 12.8% growth [2] - Total revenues for the fourth quarter were $5.32 billion, a 2% year-over-year increase, although it missed the Zacks Consensus Estimate by 0.2% [3] Revenue Details - Revenues were driven by strong performance in the U.S. market across all segments, particularly in Advanced Visualization Solutions and Pharmaceutical Diagnostics [3] - For the full year 2024, GEHC reported revenues of $19.67 billion, reflecting a 1% year-over-year increase [4] Segment Performance - Imaging segment revenues were $2.39 billion, flat year-over-year, with segment EBIT at $302 million, up 19% [5] - Advanced Visualization Solutions generated revenues of $1.44 billion, a 4% year-over-year increase, with segment EBIT at $374 million, up 15% [7] - Patient Care Solutions revenues were $827 million, flat year-over-year, with segment EBIT down 4% to $106 million [7] - Pharmaceutical Diagnostics revenues totaled $646 million, up 9% year-over-year, with segment EBIT at $212 million, up 47% [7] Margins and Cash Flow - The net income margin improved to 13.5%, up 580 basis points from the prior year, attributed to productivity and pricing benefits [8] - Cumulative cash flow from operating activities at the end of the fourth quarter was $1.96 billion, down from $2.1 billion a year ago [8] Financial Position - GEHC ended the fourth quarter with cash, cash equivalents, and investments of $2.89 billion, down from $3.57 billion in the previous quarter [9] - Total assets decreased to $33.08 billion from $33.86 billion sequentially [9] 2025 Guidance - For 2025, GE HealthCare expects adjusted EPS in the range of $4.61-$4.75, indicating a year-over-year growth of 3-6% [10] - Revenues are anticipated to grow 2-3% organically, reflecting continued demand for its products and services [10]

Core Insights - GE HealthCare Technologies reported mixed financial results for Q4 2024, with adjusted EPS of $1.45 exceeding expectations of $1.27, while revenue of $5.32 billion showed modest growth of 2% year over year [2][4][7] - The company demonstrated strong earnings performance but highlighted challenges in revenue expansion and cash flow management [3][10] Financial Performance - Adjusted EPS increased by 23% from $1.18 in Q4 2023 to $1.45 in Q4 2024 [4] - Revenue of $5.32 billion was slightly below analysts' expectations of $5.33 billion, reflecting a 2% increase from $5.21 billion in Q4 2023 [4][7] - Net income margin improved to 13.5%, up from 7.7% in the previous year, indicating enhanced profitability [4] - Free cash flow decreased by 15.2% to $811 million from $956 million in Q4 2023, suggesting a need for improved cash management [4][10] Segment Performance - The Pharmaceutical Diagnostics segment experienced significant EBIT growth of 47% year over year, with a 9% revenue increase [8] - Advanced Visualization Solutions segment revenue grew by 4%, while the Imaging segment revenue remained flat year over year, indicating stagnation in a key area [8] Strategic Initiatives - GE HealthCare focused on innovation, launching nearly 40 new products and investing $138 million in Ireland to enhance service capabilities [9] - Partnerships in AI technology, such as with Nuffield Health in the UK, reflect the company's commitment to driving future innovation and market presence [9] Future Outlook - For 2025, GE HealthCare projects organic revenue growth of 2% to 3% and adjusted EPS growth of 3% to 6%, with EBIT margin enhancement to 16.7%-16.8% [12] - The company aims to leverage strategic partnerships and innovation to navigate challenging market conditions, particularly in China [12]

Core Insights - GE HealthCare Technologies (GEHC) reported quarterly earnings of $1.45 per share, exceeding the Zacks Consensus Estimate of $1.26 per share, and up from $1.18 per share a year ago, representing an earnings surprise of 15.08% [1] - The company posted revenues of $5.32 billion for the quarter ended December 2024, slightly missing the Zacks Consensus Estimate by 0.25%, but up from $5.21 billion year-over-year [2] - GE HealthCare shares have increased approximately 9.9% since the beginning of the year, outperforming the S&P 500's gain of 2.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.98 on revenues of $4.75 billion, and for the current fiscal year, it is $4.65 on revenues of $20.38 billion [7] - The estimate revisions trend for GE HealthCare is currently unfavorable, leading to a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Products industry, to which GE HealthCare belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of GE HealthCare's stock may be influenced by the overall industry outlook, as empirical research indicates a strong correlation between near-term stock movements and earnings estimate revisions [5]

GE HealthCare (GEHC) reported better-than-expected fourth-quarter profit on Thursday, while sales were in line with analysts' estimates. The medical device maker reported adjusted earnings per share (EPS) of $1.45 on revenue of $5.32 billion. Analysts polled by Visible Alpha expected $1.26 and $5.32 billion, respectively. GE HealthCare shares, which entered the day up about 3% over the last 12 months, were little changed immediately following the report. The company said it expects year-over-year organic r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 001-41528 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 500 W. Monroe Street, Chicago, IL 60661 (Address of princip ...